Ticagrelor
Ticagrelor is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome, history of heart attack, or stroke. It works by blocking the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. This medication is typically used in combination with aspirin for optimal antiplatelet effect.
Ticagrelor is an antiplatelet drug that prevents blood clots by blocking platelet activation, used primarily in heart attack and stroke prevention.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- B01AC24
- RxNorm
- 1116632
- Generic
- Ticagrelor
- Class
- atc-b01a
- Brands
- Brilinta
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of thrombotic events in patients with acute coronary syndrome (unstable angina, non-ST elevation MI, ST elevation MI), secondary prevention of cardiovascular events in patients with a history of myocardial infarction, and reduction of thrombotic events in patients with a history of stroke or peripheral artery disease.
Ticagrelor reversibly binds to the platelet P2Y12 ADP-receptor, blocking ADP-mediated signal transduction and preventing platelet activation and aggregation. Both ticagrelor and its major metabolite are approximately equipotent in their antiplatelet activity.
Major risk is bleeding; patients should be monitored for signs of bleeding. Should not be used with strong CYP3A4 inhibitors or in patients with active pathological bleeding. Often prescribed with low-dose aspirin. Not recommended for patients with history of intracranial hemorrhage. Requires careful consideration before surgery due to prolonged antiplatelet effect.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy